|
1
|
Mitchell JK and Leslie KS: Melanoma death
prevention: Moving away from the sun. J Am Acad Dermatol.
68:e169–e175. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neagu M, Caruntu C, Constantin C, Boda D,
Zurac S, Spandidos DA and Tsatsakis AM: Chemically induced skin
carcinogenesis: Updates in experimental models (Review). Oncol Rep.
35:2516–2528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zurac S, Neagu M, Constantin C, Cioplea M,
Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et
al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in
cutaneous melanoma with regression and their possible function as
prognostic predictors. Oncol Lett. 11:3354–3360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bastian BC: The molecular pathology of
melanoma: An integrated taxonomy of melanocytic neoplasia. Annu Rev
Pathol. 9:239–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al Australian Pancreatic Cancer Genome
Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq
Consortium; ICGC PedBrain, : Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sullivan RJ: Molecular diagnostics and
tumor mutational analysis. BRAF Targets in Melanoma-Biological
Mechanisms. Resistance and Drug Discovery; Springer, New York, NY:
pp. 47–72. 2015
|
|
7
|
Carlos G, Anforth R, Clements A, Menzies
AM, Carlino MS, Chou S and Fernandez-Peñas P: Cutaneous toxic
effects of BRAF inhibitors alone and in combination with MEK
inhibitors for metastatic melanoma. JAMA Dermatol. 151:1103–1109.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bolognia JL, Schaffer JV and Cerroni L:
Neoplasms of the skin. Dermatology. 4th. Elsevier; pp. 1989–2020.
2018
|
|
9
|
Shai A, Avinoach I and Sagi A: Metastatic
malignant melanoma with spontaneous and complete regression of the
primary lesion. Case report and review of the literature. J
Dermatol Surg Oncol. 20:342–345. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ehrsam E, Kallini JR, Lebas D, Khachemoune
A, Modiano P and Cotten H: Fully regressive melanoma: A case
without metastasis. J Clin Aesthet Dermatol. 9:42–46.
2016.PubMed/NCBI
|
|
11
|
High WA, Stewart D, Wilbers CR, Cockerell
CJ, Hoang MP and Fitzpatrick JE: Completely regressed primary
cutaneous malignant melanoma with nodal and/or visceral metastases:
A report of 5 cases and assessment of the literature and diagnostic
criteria. J Am Acad Dermatol. 53:89–100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bories N, Dalle S, Debarbieux S, Balme B,
Ronger-Savlé S and Thomas L: Dermoscopy of fully regressive
cutaneous melanoma. Br J Dermatol. 158:1224–1229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dasgupta T, Bowden L and Berg JW:
Malignant melanoma of unknown primary origin. Surg Gynecol Obstet.
117:341–345. 1963.PubMed/NCBI
|
|
14
|
Smith JL Jr and Stehlin JS Jr: Spontaneous
regression of primary malignant melanomas with regional metastases.
Cancer. 18:1399–1415. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Todd DW, Farrow GM, Winkelmann RK and
Payne WS: Spontaneous regression of primary malignant melanoma with
regional metastasis: Report of a case with photographic
documentation. Mayo Clin Proc. 41:672–676. 1966.PubMed/NCBI
|
|
16
|
Milton CW, Lane Brown MM and Gilder M:
Malignant melanoma with an occult primary lesion. Br J Surg.
54:651–658. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cochran AJ, Diehl V and Stjernswärd J:
Regression of primary malignant melanoma associated with a good
prognosis despite metastasis to lymph nodes. Rev Eur Etud Clin
Biol. 15:969–972. 1970.PubMed/NCBI
|
|
18
|
McGovern VJ: Spontaneous regression of
melanoma. Pathology. 7:91–99. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
MacDougal BA, Weeks PM and Wray RC Jr:
Spontaneous regression of the primary lesion of a metastatic
malignant melanoma. Plast Reconstr Surg. 57:355–358. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whicker JH, DeMarco PR and Fitzgibbons JF:
Spontaneous regression of a facial malignant melanoma. Arch
Otolaryngol. 106:50–51. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pellegrini AE: Regressed primary malignant
melanoma with regional metastases. Arch Dermatol. 116:585–586.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Landthaler M and Braun-Falco O: Malignant
melanoma with unknown primary tumor. Case reports of 12 patients
with overview. Hautarzt. 32:339–344. 1981.(In German). PubMed/NCBI
|
|
23
|
Kessler E, Schwartz P and Antebi E:
Spontaneous regression of primary malignant melanoma with
metastases. Plast Reconstr Surg. 74:427–429. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rampen FH and Meijer J: Metastatic
melanoma of the brain after spontaneous regression of the primary.
Acta Neurol Scand. 72:222–224. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paul E and Müllhofer R: Metastasizing
malignant melanoma from unknown primary tumor. Hautarzt.
41:432–437. 1990.(In German). PubMed/NCBI
|
|
26
|
Bottger D, Dowden RV and Kay PP: Complete
spontaneous regression of cutaneous primary malignant melanoma.
Plast Reconstr Surg. 89:548–553. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Avril MF, Charpentier P, Margulis A and
Guillaume JC: Regression of primary melanoma with metastases.
Cancer. 69:1377–1381. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sais G, Marcoval J, Juggla A, Curco N and
Servitje O: Dermatomyositis and metastatic malignant melanoma, with
complete regression of the primary lesion. Br J Dermatol.
130:796–797. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Emanuel PO, Mannion M and Phelps RG:
Complete regression of primary malignant melanoma. Am J
Dermatopathol. 30:178–181. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mărgăritescu I, Chiriţă AD and Vasilescu
F: Completely regressed primary cutaneous melanoma - difficulties
in diagnosis and classification. Rom J Morphol Embryol. 55 (Suppl
2):635–642. 2014.PubMed/NCBI
|
|
31
|
Yamada S, Nawata A, Yoshioka M, Hiraki T,
Higashi M, Hatanaka K and Tanimoto A: Complete regression of
primary cutaneous malignant melanoma associated with distant lymph
node metastasis: A teaching case mimicking blue nevus. BMC Res
Notes. 9:3662016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dunn GP, Lewis JS Jr, Sunwoo JB and
Uppaluri R: Spontaneous regression of cutaneous head and neck
melanoma: Implications for the immunologic control of neoplasia.
Head Neck. 30:267–272. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Menzies SW and McCarthy WH: Complete
regression of primary cutaneous malignant melanoma. Arch Surg.
132:553–556. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khosravi H, Akabane AL, Alloo A, Nazarian
RM and Boland GM: Metastatic melanoma with spontaneous complete
regression of a thick primary lesion. JAAD Case Rep. 2:439–441.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Martín JM, Pinazo I, Monteagudo C,
Markovic J, Allende A and Jordá E: Spontaneous regression of
multiple melanocytic nevi after melanoma: Report of 3 cases. Am J
Dermatopathol. 36:e183–e188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McClenahan P, Lin LL, Tan JM,
Flewell-Smith R, Schaider H, Jagirdar K, Atkinson V, Lambie D, Prow
TW, Sturm RA, et al: BRAFV600E mutation status of involuting and
stable nevi in dabrafenib therapy with or without trametinib. JAMA
Dermatol. 150:1079–1082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Argenziano G, Zalaudek I, Corona R, Sera
F, Cicale L, Petrillo G, Ruocco E, Hofmann-Wellenhof R and Soyer
HP: Vascular structures in skin tumors: A dermoscopy study. Arch
Dermatol. 140:1485–1489. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zalaudek I, Argenziano G, Ferrara G, Soyer
HP, Corona R, Sera F, Cerroni L, Carbone A, Chiominto A, Cicale L,
et al: Clinically equivocal melanocytic skin lesions with features
of regression: A dermoscopic-pathological study. Br J Dermatol.
150:64–71. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pozzobon FC, Puig-Butillé JA,
González-Alvarez T, Carrera C, Aguilera P, Alos L, Badenas C,
Grichnik JM, Malvehy J and Puig S: Dermoscopic criteria associated
with BRAF and NRAS mutation status in primary cutaneous melanoma.
Br J Dermatol. 171:754–759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Massi G and LeBoit PE: Histological
Diagnosis of Nevi and Melanoma. Springer; Berlin, Heidelberg: pp.
385–398. 2014
|
|
41
|
Cheng L, Lopez-Beltran A, Massari F,
MacLennan GT and Montironi R: Molecular testing for BRAF mutations
to inform melanoma treatment decisions: A move toward precision
medicine. Mod Pathol. 31:24–38. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Diaconeasa A, Boda D, Solovan C, Enescu
DM, Vîlcea AM and Zurac S: Histopathologic features of Spitzoid
lesions in different age groups. Rom J Morphol Embryol. 54:51–62.
2013.PubMed/NCBI
|
|
43
|
Pollock PM, Harper UL, Hansen KS, Yudt LM,
Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J,
et al: High frequency of BRAF mutations in nevi. Nat Genet.
33:19–20. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Haenssle HA, Kraus SL, Brehmer F,
Kretschmer L, Völker B, Asper H, Kapp A and Gutzmer R: Dynamic
changes in nevi of a patient with melanoma treated with
vemurafenib: Importance of sequential dermoscopy. Arch Dermatol.
148:1183–1185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Weeraratna AT: RAF around the edges - the
paradox of BRAF inhibitors. N Engl J Med. 366:271–273. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Aung PP, Nagarajan P and Prieto VG:
Regression in primary cutaneous melanoma: Etiopathogenesis and
clinical significance. Lab Invest. 97:657–668. 2017. View Article : Google Scholar
|
|
47
|
Lupu M, Caruntu A, Caruntu C, Papagheorghe
LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki
M, et al: Neuroendocrine factors: The missing link in non-melanoma
skin cancer (Review). Oncol Rep. 38:1327–1340. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Caruntu C, Boda D, Constantin C, Caruntu A
and Neagu M: Catecholamines increase in vitro proliferation of
murine B16F10 melanoma cells. Acta Endocrinol (Copenh). 10:545–558.
2014.
|
|
49
|
Boda D: Cellomics as integrative omics for
cancer. Curr Proteomics. 10:237–245. 2013. View Article : Google Scholar
|
